Skip to main content
. 2017 Dec 8;2017(1):708–715. doi: 10.1182/asheducation-2017.1.708

Table 2.

Open studies in clinicaltrials.gov as of May 2017

Open studies (n =) clinicaltrials.gov reference
DLI
 Hematological malignancies (14) NCT02673008, NCT01240525, NCT02458235, NCT02568241, NCT02328885, NCT02331706, NCT01839916, NCT02452697, NCT01982682, NCT03032783, NCT02566395, NCT01384513, NCT02566304, NCT02199041
 MDS/AML (7) NCT02856464, NCT02472691, NCT02046122, NCT02684162, NCT01369368, NCT01758367, NCT02888522
 CLL (1) NCT01849939
 Myeloma (2) NCT01131169, NCT02700841
CTL
 Hematological malignancies (2) NCT02895412, NCT02203903
 EBV-associated malignancies (1) NCT00002663
CIK
 Leukemia/MDS (2) NCT02752243, NCT01898793
 Lymphoma (2) NCT02497898, NCT01799083
MIL
 Myeloma (1) NCT01858558
CART
 CD5 directed (1) NCT03081910
 CD19 directed (60) NCT02935543, NCT02445222, NCT02547948, NCT03142646, NCT02799550, NCT02782351, NCT02813837, NCT03029338, NCT03121625, NCT03027739, NCT02640209, NCT03086954, NCT02822326, NCT02975687, NCT01864889, NCT02735291, NCT02728882, NCT02963038, NCT03101709, NCT02924753, NCT02247609, NCT03068416, NCT02810223, NCT02965092, NCT02186860, NCT02935257, NCT02842138, NCT03064269, NCT02537977, NCT02672501, NCT02624258, NCT02794246, NCT02652910, NCT03085173, NCT02443831, NCT02819583, NCT03110640, NCT03118180, NCT02685670, NCT02030834, NCT02349698, NCT02529813, NCT02081937, NCT02030847, NCT02028455, NCT02968472, NCT03016377, NCT02546739, NCT03050190, NCT02772198, NCT03103971, NCT02228096, NCT02851589, NCT02146924, NCT01853631, NCT02374333, NCT02659943, NCT01865617, NCT02445248, NCT02631044
 CD20 directed (3) NCT02710149, NCT02965157, NCT01735604
 CD22 directed (4) NCT02794961, NCT02935153, NCT02650414, NCT02721407
 CD30 directed (6) NCT02259556, NCT02917083, NCT02958410, NCT02274584, NCT03049449, NCT02690545
 CD33 directed (4) NCT01864902, NCT02799680, NCT02958397, NCT03126864
 CD123 directed (3) NCT02937103, NCT03114670, NCT02159495
 CD133 directed (1) NCT02541370
 CD138 directed (1) NCT01886976
 BCMA directed (5) NCT02954445, NCT02546167, NCT03070327, NCT03093168, NCT02215967
 LeY directed (1) NCT02958384
 ROR1 (1) NCT02706392
 Combination (4) NCT02903810, NCT03125577, NCT03098355, NCT03097770
Vaccines
 MDS/AML (8) NCT01686334, NCT02493829, NCT03059485, NCT01734304, NCT02405338, NCT01773395, NCT03083054, NCT02498665
 CML (2) NCT02543749, NCT00363649
 CLL (1) NCT02802943
 Myeloma (1) NCT02334865
 NHL (1) NCT03035331
NK cells
 Hematological malignancies (12) NCT02280525, NCT02892695, NCT01619761, NCT01904136, NCT03056339, NCT02742727, NCT01823198, NCT00720785, NCT02727803, NCT01700946, NCT01807611, NCT02890758
 MDS/AML (14) NCT01787474, NCT02809092, NCT02763475, NCT03081780, NCT02123836, NCT03050216, NCT02229266, NCT02944162, NCT02477787, NCT02782546, NCT01898793, NCT03068819, NCT02316964, NCT02781467
 ALL (2) NCT02185781, NCT01974479

CIK, cytokine-induced killer; CML, chronic myelogenous leukemia; CTL, cytotoxic T lymphocyte; DLI, donor lymphocyte infusion; EBV, Epstein-Barr virus; MDS, myelodysplastic syndrome; MIL, marrow-infiltrating lymphocyte; NK, natural killer; ROR1, receptor tyrosine kinase like orphan receptor 1. Other abbreviations are explained in Table 1.